HC Wainwright Weighs in on Greenwich LifeSciences, Inc.’s Q1 2025 Earnings (NASDAQ:GLSI)

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Greenwich LifeSciences in a research report issued to clients and investors on Wednesday, May 22nd. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of ($0.17) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.70) EPS.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its quarterly earnings results on Monday, April 15th. The company reported ($0.21) earnings per share for the quarter.

Greenwich LifeSciences Price Performance

GLSI stock opened at $13.08 on Thursday. The firm has a market cap of $168.47 million, a PE ratio of -18.17 and a beta of 1.55. Greenwich LifeSciences has a 12 month low of $7.58 and a 12 month high of $21.44. The firm has a 50 day simple moving average of $15.37 and a 200 day simple moving average of $12.52.

Insider Buying and Selling at Greenwich LifeSciences

In related news, CEO Snehal Patel acquired 3,000 shares of Greenwich LifeSciences stock in a transaction dated Monday, April 1st. The stock was acquired at an average cost of $19.08 per share, with a total value of $57,240.00. Following the purchase, the chief executive officer now directly owns 5,350,777 shares in the company, valued at approximately $102,092,825.16. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Over the last 90 days, insiders have purchased 11,100 shares of company stock valued at $187,133. Corporate insiders own 52.86% of the company’s stock.

Institutional Trading of Greenwich LifeSciences

An institutional investor recently raised its position in Greenwich LifeSciences stock. Vanguard Group Inc. increased its position in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 0.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 223,102 shares of the company’s stock after acquiring an additional 1,420 shares during the quarter. Vanguard Group Inc. owned 1.73% of Greenwich LifeSciences worth $4,449,000 as of its most recent SEC filing. 4.16% of the stock is owned by institutional investors.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.